Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse.
Amir T. Fathi(University of Southern California), Richard M. Stone(Dana-Farber Cancer Institute), Yi-Bin Albert Chen(Harvard University), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Meghan Burke(Harvard University), David P. Schenkein(Agios Pharmaceuticals (United States)), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Kimberly Straley(Agios Pharmaceuticals (United States)), Katharine Yen(Agios Pharmaceuticals (United States)), A. John Iafrate(Massachusetts General Hospital), Sophia Adamia(Beth Israel Deaconess Medical Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Julia Foster(Harvard University), Donna Neuberg(Otsuka (Japan)), Suiyang Liu(Dana-Farber Cancer Institute), Philip C. Amrein(Massachusetts General Hospital)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k